Correction to: Collating the voice of people with autoimmune diseases: Methodology for the third phase of the COVAD studies
- PMID: 39400562
- PMCID: PMC11618184
- DOI: 10.1007/s00296-024-05692-4
Correction to: Collating the voice of people with autoimmune diseases: Methodology for the third phase of the COVAD studies
Keywords: Autoimmune diseases; Correction; Digital health; Quality of life; Sociodemographic factors; Survey.
Conflict of interest statement
Declarations. Conflicts of Interest: ALT has received honoraria for advisory boards and speaking for Abbvie, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. EN has received speaker honoraria/participated in advisory boards for Celltrion, Pfizer, Sanofi, Gilead, Galapagos, AbbVie, and Lilly, and holds research grants from Pfizer and Lilly. HC has received consulting fees as a speaker for GSK, UCB; Advisory Board member for Astra Zeneca, Pfizer, Argenx, Galapagos; Data and Science Monitoring Board chair for Horizon Therapeutics. IP has received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Elli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis and F. Hoffmann-La Roche AG. JD has received research funding from CSL Limited. KC is a patient living with myositis and serves on the board of International Myositis Society, patient advisory group of the MIHRA foundation and EU patient advocacy for MSU. LK works at The Myositis Association which receives support from Octapharma, Mallinckrodt, Pfizer, argenx, Alexion, Janssen, Abcuro, Priovant, Horizon, and EMD Serono. MK has received speaker honoraria/participated in advisory boards for Asahi-Kasei, AstraZeneca, Boehringer-Ingelheim, Chugai, isai, GSK, Kissei, BML, Mochida, Nippon Shinyaku, Ono Pharmaceuticals, and Tanabe-Mitsubishi. ND has received consulting fees, speaker fees or grants from AstraZeneca, Novartis, Horizon, Selecta, Arthrosi, JW Pharmaceutical Corporation, PK Med, LG Chem, JPI, PTC Therapeutics, Protalix, Unlocked Labs, Hikma, Dexoligo Therapeutics. NZ has received speaker fees, advisory board fees, and research grants from Pfizer, Roche, Abbvie, Eli Lilly, NewBridge, Sanofi-Aventis, Boehringer Ingelheim, Janssen, and Pierre Fabre; none are related to this manuscript. TV has received speaker honoraria from Pfizer and AstraZeneca, non-related to the current manuscript. The rest of the authors have no conflict of interest relevant to this manuscript. Ethical approval: The ethical approval has been obtained from the Institutional Ethics Committee at the SGPGIMS, Raebareli Road, Lucknow, India, postal code 226014. Disclaimer: No part of this manuscript has been copied or published elsewhere, either in whole or in part.
Erratum for
-
Collating the voice of people with autoimmune diseases: Methodology for the Third Phase of the COVAD Studies.Rheumatol Int. 2024 Jul;44(7):1233-1244. doi: 10.1007/s00296-024-05562-z. Epub 2024 Apr 12. Rheumatol Int. 2024. PMID: 38609655 Free PMC article.
References
-
- Kadam, E., Javaid, M., Sen, P., Saha, S., Ziade, N., Day, J., Wincup, C., Andreoli, L., Parodis, I., Tan, A. L., Shinjo, S. K., Dey, D., Cavagna, L., Chatterjee, T., Knitza, J., Wang, G., Dalbeth, N., Velikova, T., Battista, S., … Gupta, L. (2024). Collating the voice of people with autoimmune diseases: Methodology for the Third Phase of the COVAD Studies. Rheumatology International. 10.1007/s00296-024-05562-z - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
